The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) have announced the release of the 2016 update of the AACE/ACE Comprehensive Diabetes Management Algorithm and Executive Summary to guide physicians in the management of patients with type 2 diabetes

The 2016 algorithm takes into account new treatments, disease management, and key clinical data. It includes a new lifestyle therapy optimization section; a complications-centric model for overweight/obese patients with an analysis of currently available obesity treatments; further stratification of therapy choices based on the patient’s initial A1C level; and a detailed overview of all the antihyperglycemic, antihypertensive, and lipid-lowering medications approved by the Food and Drug Administration (FDA) through December 2015.

RELATED: Guideline-Concordant Diabetes Care Similar With NPs, PCPs

The new update highlights obesity and prediabetes as underlying risk factors for the development of type 2 diabetes and other macrovascular complications.  Further, the algorithm includes recommendations for blood pressure and lipid control, which are cited as the two most important risk factors for cardiovascular disease

The algorithm emphasizes the importance of making safe therapy choices in order to minimize or avoid hypoglycemia and its serious complications. In addition, the algorithm provides clinical guidance on establishing and maintaining optimal A1C and glycemic targets, minimizing weight gain, and its related complications, and managing type 2 diabetes comorbidities such as insulin resistance, macro-and microvascular complications, hypertension, cardiovascular disease, and lipid disorders. A summary chart on the attributes of each antihyperglycemic class and the algorithm principles follow at the end. 

The 2016 algorithm and executive summary can be found online and in the January 2016 issue of Endocrine Practice.

For more information visit